CN103209694A - 用于治疗视网膜疾病的[3-(1-(1h-咪唑-4-基)乙基)-2-甲基苯基]甲醇的酯前药 - Google Patents

用于治疗视网膜疾病的[3-(1-(1h-咪唑-4-基)乙基)-2-甲基苯基]甲醇的酯前药 Download PDF

Info

Publication number
CN103209694A
CN103209694A CN2011800546049A CN201180054604A CN103209694A CN 103209694 A CN103209694 A CN 103209694A CN 2011800546049 A CN2011800546049 A CN 2011800546049A CN 201180054604 A CN201180054604 A CN 201180054604A CN 103209694 A CN103209694 A CN 103209694A
Authority
CN
China
Prior art keywords
methyl
ethyl
imidazol
alkyl
benzyl ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800546049A
Other languages
English (en)
Chinese (zh)
Inventor
M·I·蒂巴斯
D·W·吉尔
周健雄
王黎明
M·E·贾斯特
J·E·多纳罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44675870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103209694(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CN103209694A publication Critical patent/CN103209694A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2011800546049A 2010-09-16 2011-09-16 用于治疗视网膜疾病的[3-(1-(1h-咪唑-4-基)乙基)-2-甲基苯基]甲醇的酯前药 Pending CN103209694A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38337010P 2010-09-16 2010-09-16
US61/383,370 2010-09-16
PCT/US2011/051926 WO2012037453A1 (en) 2010-09-16 2011-09-16 Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases

Publications (1)

Publication Number Publication Date
CN103209694A true CN103209694A (zh) 2013-07-17

Family

ID=44675870

Family Applications (5)

Application Number Title Priority Date Filing Date
CN2011800546049A Pending CN103209694A (zh) 2010-09-16 2011-09-16 用于治疗视网膜疾病的[3-(1-(1h-咪唑-4-基)乙基)-2-甲基苯基]甲醇的酯前药
CN201180053886.0A Active CN103200941B (zh) 2010-09-16 2011-09-16 用于降低眼内压的[3-(1-(1h-咪唑-4-基)乙基)-2-甲基苯基]甲醇的酯前药
CN201510767798.7A Active CN105412092B (zh) 2010-09-16 2011-09-16 用于降低眼内压的[3-(1-(1h-咪唑-4-基)乙基)-2-甲基苯基]甲醇的酯前药
CN2011800545690A Pending CN103221045A (zh) 2010-09-16 2011-09-16 用于治疗皮肤疾病和病状的[3-(1-(1h-咪唑-4-基)乙基)-2-甲基苯基]甲醇的酯前药
CN201180053895XA Pending CN103200942A (zh) 2010-09-16 2011-09-16 [3-(1-(1h-咪唑-4-基)乙基)-2-甲基苯基]甲醇的酯前药

Family Applications After (4)

Application Number Title Priority Date Filing Date
CN201180053886.0A Active CN103200941B (zh) 2010-09-16 2011-09-16 用于降低眼内压的[3-(1-(1h-咪唑-4-基)乙基)-2-甲基苯基]甲醇的酯前药
CN201510767798.7A Active CN105412092B (zh) 2010-09-16 2011-09-16 用于降低眼内压的[3-(1-(1h-咪唑-4-基)乙基)-2-甲基苯基]甲醇的酯前药
CN2011800545690A Pending CN103221045A (zh) 2010-09-16 2011-09-16 用于治疗皮肤疾病和病状的[3-(1-(1h-咪唑-4-基)乙基)-2-甲基苯基]甲醇的酯前药
CN201180053895XA Pending CN103200942A (zh) 2010-09-16 2011-09-16 [3-(1-(1h-咪唑-4-基)乙基)-2-甲基苯基]甲醇的酯前药

Country Status (28)

Country Link
US (9) US8492557B2 (https=)
EP (13) EP3050564B1 (https=)
JP (4) JP2013541527A (https=)
KR (7) KR101952457B1 (https=)
CN (5) CN103209694A (https=)
AR (4) AR083018A1 (https=)
AU (4) AU2011301932C1 (https=)
BR (4) BR112013006362A2 (https=)
CA (8) CA2812191C (https=)
CL (4) CL2013000735A1 (https=)
CY (3) CY1121024T1 (https=)
DK (9) DK2616068T3 (https=)
ES (10) ES2607084T3 (https=)
HU (5) HUE047476T2 (https=)
IL (4) IL225280A0 (https=)
MX (4) MX2013003004A (https=)
MY (4) MY161607A (https=)
NZ (1) NZ608751A (https=)
PL (7) PL3348264T3 (https=)
PT (7) PT2616069T (https=)
RU (4) RU2013116405A (https=)
SG (4) SG188571A1 (https=)
SI (5) SI3348264T1 (https=)
TR (1) TR201909249T4 (https=)
TW (4) TW201240661A (https=)
UA (1) UA112973C2 (https=)
WO (4) WO2012037453A1 (https=)
ZA (4) ZA201302193B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3241553B1 (en) * 2009-02-13 2019-04-10 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
MX344303B (es) 2010-01-11 2016-12-13 Orexigen Therapeutics Inc Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
US8492557B2 (en) * 2010-09-16 2013-07-23 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol
CA2842866A1 (en) * 2011-07-22 2013-01-31 Allergan, Inc. Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye
EP2782569A1 (en) 2011-11-21 2014-10-01 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
USD794650S1 (en) 2014-11-28 2017-08-15 Samsung Electronics Co., Ltd. Display screen or portion thereof with a graphical user interface
CN108310442B (zh) * 2017-01-17 2021-08-27 台北科技大学 眼科用组合物
KR102050506B1 (ko) 2017-06-20 2019-11-29 한국식품연구원 망막 질환 예방, 개선, 완화 또는 치료용 조성물
CN108872431B (zh) * 2018-07-09 2021-03-23 成都倍特药业股份有限公司 一种检测4-(1-(2,5-二甲基苯基)乙基)-1h-咪唑或/和其盐酸盐的方法
JP7584802B2 (ja) * 2018-08-24 2024-11-18 アドライ・ノーティ・バイオファーマ・カンパニー・リミテッド 高活性ｓｔｉｎｇタンパク質アゴニスト
WO2022221071A1 (en) * 2021-04-16 2022-10-20 Ads Therapeutics Llc Alpha2 adrenergic agonist codrugs conjugated with muscarinic agonist drugs
AU2024217271A1 (en) * 2023-02-08 2025-09-18 Bausch + Lomb Ireland Limited Alpha-2-adrenergic agonists for improving vision
WO2025179071A1 (en) * 2024-02-20 2025-08-28 Bausch + Lomb Ireland Limited Sustained-release drug delivery compositions for treating ocular diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009089132A1 (en) * 2008-01-09 2009-07-16 Allergan, Inc. Substituted-aryl-2-phenylethyl-1h-imidazole compounds as subtype selective modulators of alpha 2b and/or alpha 2c adrenergic receptors
WO2010093930A1 (en) * 2009-02-13 2010-08-19 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
CN103200941A (zh) * 2010-09-16 2013-07-10 阿勒根公司 用于降低眼内压的[3-(1-(1h-咪唑-4-基)乙基)-2-甲基苯基]甲醇的酯前药

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69307505T2 (de) 1992-05-13 1997-07-24 Sandoz-Patent-Gmbh, 79539 Loerrach Opthalmische zusammensetzungen enthaltend ein cyclosporin
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
ATE234290T1 (de) 1993-11-15 2003-03-15 Schering Corp Phenylalkyl-imidazole als h3-rezeptor- antagonisten
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
MXPA05012679A (es) * 2003-05-27 2006-02-08 Sod Conseils Rech Applic Nuevos derivados de imidazoles, su preparacion y su uso como medicamento.
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20060209374A1 (en) * 2003-07-14 2006-09-21 Koninklijke Philips Electronics N.V. Projection device
MXPA06002716A (es) * 2003-09-12 2006-06-06 Allergan Inc Metodos y composiciones para el tratamiento de dolor y otras condiciones mediadas por adrenergicos de alfa-2.
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
JP4955543B2 (ja) 2004-05-25 2012-06-20 サンズローザ ファーマシューティカル ディヴェロップメント インコーポレイテッド 炎症性皮膚疾患を治療又は予防するための化合物、製剤及び方法
US20050277584A1 (en) 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
NZ553341A (en) 2004-09-24 2010-11-26 Allergan Inc 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US20070082070A1 (en) * 2005-10-11 2007-04-12 Stookey Evangeline L Treating skin disorders
JP2012517433A (ja) 2009-02-06 2012-08-02 アラーガン インコーポレイテッド アルファ２ｂおよび／またはアルファ２ｃアドレナリンレセプターのサブタイプ選択的モジュレーターとしてのピリジン化合物
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009089132A1 (en) * 2008-01-09 2009-07-16 Allergan, Inc. Substituted-aryl-2-phenylethyl-1h-imidazole compounds as subtype selective modulators of alpha 2b and/or alpha 2c adrenergic receptors
WO2010093930A1 (en) * 2009-02-13 2010-08-19 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
CN103200941A (zh) * 2010-09-16 2013-07-10 阿勒根公司 用于降低眼内压的[3-(1-(1h-咪唑-4-基)乙基)-2-甲基苯基]甲醇的酯前药
CN103221045A (zh) * 2010-09-16 2013-07-24 阿勒根公司 用于治疗皮肤疾病和病状的[3-(1-(1h-咪唑-4-基)乙基)-2-甲基苯基]甲醇的酯前药

Also Published As

Publication number Publication date
IL225278A (en) 2015-11-30
WO2012037490A1 (en) 2012-03-22
CL2013000734A1 (es) 2013-11-08
TW201240662A (en) 2012-10-16
UA112973C2 (uk) 2016-11-25
AU2011301901B2 (en) 2016-02-11
PT2616068T (pt) 2016-09-13
CN103221045A (zh) 2013-07-24
EP2616069A1 (en) 2013-07-24
CL2013000736A1 (es) 2013-07-12
CA2812197C (en) 2024-01-02
CA2812191A1 (en) 2012-03-22
US20130289088A1 (en) 2013-10-31
AU2011301932B2 (en) 2016-02-25
US8492422B2 (en) 2013-07-23
BR112013006352A2 (pt) 2016-06-28
PL3348264T3 (pl) 2020-08-24
US20120136036A1 (en) 2012-05-31
EP3338777B1 (en) 2020-02-05
EP3050563B1 (en) 2018-05-09
DK2616069T3 (en) 2016-12-19
AU2011301856A1 (en) 2013-05-02
US20160354346A1 (en) 2016-12-08
EP2616067A1 (en) 2013-07-24
US20140057958A1 (en) 2014-02-27
CN103200941A (zh) 2013-07-10
RU2013116405A (ru) 2014-10-27
IL225280A0 (en) 2013-06-27
PL2616069T3 (pl) 2017-04-28
PL2616068T3 (pl) 2016-11-30
HUE047476T2 (hu) 2020-04-28
DK3338777T3 (da) 2020-04-20
MY191369A (en) 2022-06-20
HUE038698T2 (hu) 2018-11-28
HK1185538A1 (zh) 2014-02-21
EP3050564B1 (en) 2019-09-04
CA3077732A1 (en) 2012-03-22
PL3338777T3 (pl) 2020-07-13
MY168763A (en) 2018-12-04
MX2013003002A (es) 2013-06-28
EP3636263B1 (en) 2021-11-03
EP3053576A1 (en) 2016-08-10
HK1185541A1 (zh) 2014-02-21
TWI591058B (zh) 2017-07-11
EP3050564A1 (en) 2016-08-03
RU2612351C2 (ru) 2017-03-07
US8492557B2 (en) 2013-07-23
EP2616068A1 (en) 2013-07-24
BR112013006320A2 (pt) 2016-06-21
AU2011301932C1 (en) 2016-09-01
CN103200941B (zh) 2015-12-16
CN103200942A (zh) 2013-07-10
PT2616069T (pt) 2016-12-06
SG188572A1 (en) 2013-04-30
ES2760920T3 (es) 2020-05-18
WO2012037484A1 (en) 2012-03-22
KR20140005154A (ko) 2014-01-14
ZA201302291B (en) 2013-11-27
PT3053576T (pt) 2018-10-08
AR083019A1 (es) 2013-01-23
KR20190022895A (ko) 2019-03-06
ES2788051T3 (es) 2020-10-20
EP3078376B1 (en) 2019-03-27
HK1257416A1 (en) 2019-10-18
ZA201302288B (en) 2013-11-27
US20150148394A1 (en) 2015-05-28
JP6045495B2 (ja) 2016-12-14
DK3050563T3 (en) 2018-08-13
MX2013003008A (es) 2013-06-28
PL3050564T3 (pl) 2020-06-01
KR101952457B1 (ko) 2019-02-26
KR102354097B1 (ko) 2022-01-20
SG188571A1 (en) 2013-04-30
DK3050564T3 (da) 2019-11-25
US20130296394A1 (en) 2013-11-07
SI3050563T1 (sl) 2018-10-30
SI3050564T1 (sl) 2020-02-28
AU2011301932A1 (en) 2013-05-02
KR20130114140A (ko) 2013-10-16
JP6073229B2 (ja) 2017-02-01
KR20200044147A (ko) 2020-04-28
EP2616068B1 (en) 2016-07-13
HK1185540A1 (en) 2014-02-21
DK3078376T3 (da) 2019-06-24
CA2812191C (en) 2021-04-13
EP3636263A1 (en) 2020-04-15
US8853251B2 (en) 2014-10-07
CY1121024T1 (el) 2019-12-11
HUE049573T2 (hu) 2020-10-28
MX2013003009A (es) 2013-06-28
PL3053576T3 (pl) 2018-11-30
SG188570A1 (en) 2013-04-30
EP3053576B1 (en) 2018-05-16
TW201305117A (zh) 2013-02-01
AR083017A1 (es) 2013-01-23
BR112013006362A2 (pt) 2016-06-28
KR20140003407A (ko) 2014-01-09
CA2812195A1 (en) 2012-03-22
KR101840501B1 (ko) 2018-05-04
US8653123B2 (en) 2014-02-18
KR102104760B1 (ko) 2020-04-27
CL2013000733A1 (es) 2013-08-23
ES2781681T3 (es) 2020-09-04
US20120149746A1 (en) 2012-06-14
ZA201302194B (en) 2013-11-27
EP2616066A1 (en) 2013-07-24
AU2011301847B2 (en) 2016-02-11
US8501796B2 (en) 2013-08-06
SI3348264T1 (sl) 2020-07-31
AU2011301847A1 (en) 2013-05-02
EP2616067B1 (en) 2016-05-18
HUE048725T2 (hu) 2020-09-28
ES2593612T3 (es) 2016-12-12
BR112013006355A2 (pt) 2016-06-28
WO2012037499A1 (en) 2012-03-22
DK3348264T3 (da) 2020-03-23
HUE039090T2 (hu) 2018-12-28
PT3338777T (pt) 2020-05-06
SI3053576T1 (sl) 2018-11-30
EP3659600A1 (en) 2020-06-03
EP3338777A1 (en) 2018-06-27
AR083018A1 (es) 2013-01-23
MY161607A (en) 2017-04-28
SG188573A1 (en) 2013-04-30
BR112013006320B1 (pt) 2022-08-30
EP2616066B1 (en) 2016-07-13
AU2011301856C1 (en) 2016-09-08
KR101840500B1 (ko) 2018-03-20
CA2811559A1 (en) 2012-03-22
RU2013116403A (ru) 2014-10-27
CN105412092B (zh) 2020-11-17
TW201305116A (zh) 2013-02-01
EP3050563A1 (en) 2016-08-03
CN105412092A (zh) 2016-03-23
PT3050563T (pt) 2018-10-01
PT3050564T (pt) 2019-12-11
CL2013000735A1 (es) 2013-11-29
KR20130105658A (ko) 2013-09-25
RU2013116763A (ru) 2014-10-27
CY1122958T1 (el) 2021-10-29
RU2013116541A (ru) 2014-10-27
CA3079450A1 (en) 2012-03-22
EP3078376A1 (en) 2016-10-12
KR20200091507A (ko) 2020-07-30
US20120142746A1 (en) 2012-06-07
ZA201302193B (en) 2013-11-27
ES2687420T3 (es) 2018-10-25
CA2812197A1 (en) 2012-03-22
PL3050563T3 (pl) 2018-12-31
EP3348264A1 (en) 2018-07-18
WO2012037453A1 (en) 2012-03-22
JP2013540749A (ja) 2013-11-07
JP2013537236A (ja) 2013-09-30
PT3348264T (pt) 2020-04-02
MY173846A (en) 2020-02-24
KR102139905B1 (ko) 2020-07-31
DK3053576T3 (en) 2018-08-20
IL225282A0 (en) 2013-06-27
AU2011301901A1 (en) 2013-05-02
EP3348264B1 (en) 2020-01-01
ES2737230T3 (es) 2020-01-10
TW201240661A (en) 2012-10-16
ES2904479T3 (es) 2022-04-05
JP2013541527A (ja) 2013-11-14
US20120122945A1 (en) 2012-05-17
HK1185539A1 (zh) 2014-02-21
NZ608751A (en) 2015-04-24
SI3338777T1 (sl) 2020-08-31
ES2684055T3 (es) 2018-10-01
MX2013003004A (es) 2013-06-28
AR083020A1 (es) 2013-01-23
DK2616068T3 (en) 2016-08-29
CA3122745A1 (en) 2012-03-22
DK3636263T3 (da) 2022-01-10
IL225278A0 (en) 2013-06-27
EP3698789A1 (en) 2020-08-26
ES2607084T3 (es) 2017-03-29
TR201909249T4 (tr) 2019-07-22
CY1122809T1 (el) 2021-05-05
ES2613509T3 (es) 2017-05-24
EP2616069B1 (en) 2016-11-16
IL225281A0 (en) 2013-06-27
JP2013537237A (ja) 2013-09-30
CA3116249A1 (en) 2012-03-22

Similar Documents

Publication Publication Date Title
CN103209694A (zh) 用于治疗视网膜疾病的[3-(1-(1h-咪唑-4-基)乙基)-2-甲基苯基]甲醇的酯前药
HK1185539B (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]methanol for treating retinal diseases
HK40036790A (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure
HK1257416B (en) Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130717